FDA slaps back small-cap's bid to repurpose 50-year-old chemotherapy

When the German drugmaker Medac handed off a decades-old cancer compound to their US subsidiary in February, it thought it would be smooth sailing to market. After all, the drug had recently been approved in Europe and was available in Canada.